KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of SalesDeferred RevenueEmployee StatisticsGovernment Contracts Revenue By CategoryGrants And Other Revenue By CategoryGrants And Other Revenue By Category AnnualGross Margin %Gross ProfitIncome (Loss) Before Income TaxOperating Expense SegregationOpex As % Of Total Revenue %Product Sales Revenue By GeographyProduct Sales Revenue By Geography AnnualProfitabilityProfitability %Profitability AnnualProfitability Annual %Property And Equipment, Net BreakdownPurchase Commitments AnnualRemaining Performance ObligationRemaining Performance Obligations AnnualRevenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Gross Profit: 2009-2025

Historic Gross Profit for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to $48.9 million.

  • Novavax's Gross Profit rose 104.87% to $48.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $912.8 million, marking a year-over-year increase of 61.80%. This contributed to the annual value of $479.4 million for FY2024, which is 25.08% down from last year.
  • Per Novavax's latest filing, its Gross Profit stood at $48.9 million for Q3 2025, which was down 69.34% from $159.7 million recorded in Q2 2025.
  • Novavax's 5-year Gross Profit high stood at $688.8 million for Q1 2022, and its period low was -$85.2 million during Q2 2022.
  • Its 3-year average for Gross Profit is $180.0 million, with a median of $88.1 million in 2023.
  • As far as peak fluctuations go, Novavax's Gross Profit surged by 13,143.38% in 2021, and later plummeted by 128.57% in 2022.
  • Over the past 5 years, Novavax's Gross Profit (Quarterly) stood at $222.2 million in 2021, then dropped by 20.96% to $175.6 million in 2022, then decreased by 22.36% to $136.4 million in 2023, then tumbled by 62.13% to $51.6 million in 2024, then soared by 104.87% to $48.9 million in 2025.
  • Its Gross Profit stands at $48.9 million for Q3 2025, versus $159.7 million for Q2 2025 and $652.5 million for Q1 2025.